Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against<i>Klebsiella pneumoniae</i>—authors’ response-Reference-Cited by-同舟云学术

Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model againstKlebsiella pneumoniae—authors’ response

Published:2023-01-30 Issue:3 Volume:78 Page:854-857
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Sumi Chandra Datta¹^ORCID,Roberts Jason A¹²³⁴^ORCID,Sime Fekade B¹^ORCID

Affiliation:

1. The University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland , Brisbane, Queensland , Australia

2. Department of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women’s Hospital , Brisbane, Queensland , Australia

3. Herston Infectious Diseases Institute (HeIDI), Metro North Health , Brisbane , Australia

4. Division of Anaesthesiology Critical Care Emergency and Pain Medicine, Nîmes University Hospital, University of Montpellier , Nîmes , France

Funder

Australian National Health

Medical Research Council

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

https://academic.oup.com/jac/article-pdf/78/3/854/49376283/dkad017.pdf

Reference11 articles.

1. Comment on: Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Klebsiella pneumoniae;Giry;J Antimicrob Chemother,2022

2. Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis;Mueller;Antimicrob Agents Chemother,2002

3. Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements;Ulldemolins;J Antimicrob Chemother,2016

4. Generating robust and informative nonclinical in vitro and in vivo bacterial infection model efficacy data to support translation to humans;Bulitta;Antimicrob Agents Chemother,2019

5. Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting;Sadouki;J Antimicrob Chemother,2021